Shopping Cart
- Remove All
- Your shopping cart is currently empty
Antitumor agent-86 (compound 5a) demonstrates efficacy against MCF-7 breast cancer cells with an inhibitory concentration (IC 50) of 2.62 µM, promoting apoptosis and cell cycle arrest by disrupting the RAS/PI3K/Akt/JNK signaling pathways [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | 8-10 weeks | |
50 mg | Inquiry | 8-10 weeks |
Description | Antitumor agent-86 (compound 5a) demonstrates efficacy against MCF-7 breast cancer cells with an inhibitory concentration (IC 50) of 2.62 µM, promoting apoptosis and cell cycle arrest by disrupting the RAS/PI3K/Akt/JNK signaling pathways [1]. |
In vitro | Antitumor agent-86, administered at concentrations ranging from 0-200 μM for 48 hours, dose-dependently suppresses proliferation in MCF-7, MDA-MB-231, Caco-2, and PANC-1 cancer cell lines, with respective IC50 values of 2.617, 6.778, 14.8, and 23.58 μM [1]. At a concentration of 2.62 μM over 48 hours, it induces apoptosis, cell cycle arrest, reduces levels of p-RAS protein in MCF-7 cells, decreases mRNA transcription levels of PI3K and Akt, and lowers the expression of p-JNK protein [1]. Furthermore, Antitumor agent-86 upregulates the expression of the p21 gene at the same concentration and duration [1]. |
Molecular Weight | 513.65 |
Formula | C29H31N5O2S |
Cas No. | 2907704-65-6 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.